CX3CL1 and prostate cancer: Based on the above, it is speculated that the possible mechanism by which CX3CR1 on CD14+ CD16− monocytes promotes prostate cancer development is through the CX3CR1/CX3CL1 signaling pathway, promoting tumor angiogenesis, migration, and infiltration, while inhibiting ADCC, thereby weakening the body’s anti-tumor effects.